Try our Advanced Search for more refined results
Life Sciences
-
March 11, 2026
MoFo Private Equity Atty Joins Greenberg Traurig In Miami
Greenberg Traurig LLP announced Wednesday that a Miami-based private equity attorney has joined the firm's corporate practice from Morrison Foerster LLP.
-
March 11, 2026
Biomedical Co. Settles Trade Secrets Case Against Ex-Worker
Biomedical company Skye Orthobiologics and a former employee have informed a California federal judge that they have settled a case accusing the ex-employee of breaching fiduciary duties by leveraging Skye's proprietary information.
-
March 11, 2026
Investor Urges Revival Of Armistice Insider Trading Claims
The Delaware Supreme Court has heard arguments over whether a hedge fund that traded tens of millions of dollars' worth of stock can face insider trading liability under state law after its board designee allegedly received confidential company information, with an Aytu BioPharma shareholder urging the court to revive claims against healthcare investor Armistice Capital.
-
March 10, 2026
Justices Advised To Keep Law Clear In 'Skinny Label' Case
Several intellectual property groups have urged the U.S. Supreme Court to use a case involving "skinny labels" on generic drugs to set clear guidelines on what constitutes induced patent infringement, saying the outcome has implications beyond pharmaceuticals.
-
March 10, 2026
J&J Unit Wins Sanction In Talc Libel Case
A Virginia federal judge on Tuesday issued sanctions against a doctor being sued by a Johnson & Johnson unit over an article linking mesothelioma with talc products, saying that a jury will be told that he deleted emails about the article when he was legally obligated to keep them.
-
March 10, 2026
5th Circ. Revives J&J Sales Rep's Wage Dispute
A Texas federal court did not take into consideration relevant factors to determine whether a former Johnson & Johnson sales representative's failure to retain local counsel in his wage and hour suit represented excusable neglect, the Fifth Circuit ruled on Tuesday.
-
March 10, 2026
Sanofi Says Judge Botched Insulin Device Patent Listings
Sanofi-Aventis sparred with drug wholesalers over a Massachusetts federal magistrate judge's pronouncements that the parties should go to trial on claims the pharmaceutical giant used improper insulin device patent listings to anticompetitively protect the blockbuster Lantus insulin pen from competition.
-
March 10, 2026
Lab's Aetna Payment Suit Survives, But With Deep Cuts
A Connecticut federal judge ruled Aetna and its parent company, CVS Health Corp., must face a pared down lawsuit from a medical laboratory alleging it is owed $20.6 million in unpaid invoices.
-
March 10, 2026
FDA To Consider Coffee, 'Spice' E-Cig Flavors
The U.S. Food and Drug Administration on Monday indicated that it would be willing to consider e-cigarette flavors shown to be less attractive to youth, like coffee or spices, a move that's come under fire from public health advocates.
-
March 10, 2026
CVS Can't 'Relitigate' Price-Gouging Class Cert.
A Rhode Island federal judge refused to narrow the certified classes of health plans alleging CVS schemed with pharmacy benefit managers to overcharge insured health plans for generic drugs, finding that PBM Express Scripts' refusal to produce its contracts changes nothing about how the classes will be assessed.
-
March 10, 2026
Former Conn. Prosecutor Can Stay On Generic-Drug Case
Connecticut's former assistant attorney general can continue to represent insurers Humana and Molina Healthcare Inc. in multidistrict litigation over alleged price-fixing of generic drugs, after the Pennsylvania federal judge overseeing the case agreed Monday with a report that the attorney has no information that had not already been shared.
-
March 10, 2026
Medtronic Expands Vascular Device Line With $550M Deal
Medtronic said Tuesday it will acquire privately held Scientia Vascular for about $550 million, strengthening its portfolio of devices used to treat stroke and other neurovascular conditions.
-
March 10, 2026
J&J Opposes Beasley Allen Reinstatement Bid In NJ Talc Fight
Johnson & Johnson is urging the New Jersey Supreme Court to not take the "extraordinary step" of intervening in an appellate panel ruling that disqualified Beasley Allen from representing hundreds of women in product liability litigation against the pharmaceutical giant after the Georgia-based firm "knowingly collaborated" with a former Johnson & Johnson outside counsel.
-
March 09, 2026
Texas AG Gets Temporary Ban On Chest Binder Sales
A Texas state judge has issued a temporary restraining order against a New York-based online retailer of undergarments and chest binders for young women and teens from selling its clothing in the Lone Star State.
-
March 09, 2026
Abortion Rights Group, SD Agree to End Gas Station Ads Row
An abortion rights group can no longer post advertisements at gas stations in South Dakota that promote abortion care, the South Dakota attorney general's office announced on Monday, saying that the group and the state have reached an agreement in a pair of lawsuits over the advertising campaign.
-
March 09, 2026
Novo, Hims & Hers Make Up, Agree To Sell GLP-1s Together
Novo Nordisk A/S will start selling its GLP-1 medications on Hims & Hers Health Inc.'s platform as part of a deal that resolves the pharmaceutical company's patent infringement lawsuit against the telehealth provider, the companies announced Monday.
-
March 09, 2026
Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says
Brass of Ultragenyx Pharmaceutical Inc. are facing shareholder derivative claims they caused the company to overstate prospects for a drug to treat a bone disease, hurting investors and opening the company up to liability when its share prices fell following disappointing clinical trial news.
-
March 09, 2026
Astellas Prevails In Patent Battle Over Bladder Drug
A Delaware federal judge has held that Ascent Pharmaceuticals infringed four patents covering bladder medication Myrbetriq held by name-brand drugmaker Astellas Pharma Inc. and rejected Ascent's invalidity defenses.
-
March 09, 2026
McGuireWoods Beats Sun Pharma's DQ Bid In NJ Suit
A New Jersey federal court has denied Sun Pharmaceutical's bid to disqualify McGuireWoods LLP from representing pharmaceutical company Biofrontera in litigation over the alleged breach of a settlement agreement, ruling the firm's continued representation won't harm Sun Pharmaceutical and will avoid significant harm to Biofrontera.
-
March 09, 2026
Sullivan & Cromwell Advises Agilent On $950M Biocare Buy
Agilent Technologies Inc. agreed to acquire Biocare Medical, a specialist in clinical and research pathology solutions, in an all-cash transaction valued at $950 million, the company said Monday.
-
March 09, 2026
JPMorgan Trims But Can't Escape ERISA Drug Costs Suit
A New York federal judge pared claims Monday against JPMorgan Chase & Co. in a suit from workers who alleged they paid too much for prescription drugs, but opened discovery on allegations that the bank's contract with its pharmacy benefit manager caused transactions prohibited by federal benefits law.
-
March 06, 2026
Atty Should've Checked Docket, Says Philips CPAP Judge
An attorney and his client have no one but themselves to blame for the permanent end to a product liability lawsuit over a recalled Philips sleep breathing machine, a Pennsylvania federal judge said on Friday, saying it was on them to monitor the docket.
-
March 06, 2026
ExThera Exec Hid Patient Deaths To Keep $10M Deal, DOJ Says
Medical device company ExThera concealed the deaths of two U.S. patients treated with its unapproved blood filtration device at a clinic in Antigua, according to federal prosecutors, with the company agreeing to forfeit nearly $5.7 million and one executive facing up to three years in prison.
-
March 06, 2026
FDA Vaccine Chief Prasad To Exit Agency For 2nd Time
Dr. Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, will leave the agency in the coming weeks, FDA Commissioner Marty Makary said Friday.
-
March 06, 2026
Drugmaker Nektar Faces Suit Over Hair Loss Drug Trial Claims
Pharmaceutical company Nektar Therapeutics on Friday was hit with a proposed class action accusing it of harming investors by failing to disclose the risks associated with its failure to follow protocol for enrolling participants in an unsuccessful trial for its hair loss treatment.
Expert Analysis
-
Learning From 2025 FCA Trends Targeting PE In Healthcare
False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.
-
Software Patents May Face New Eligibility Scrutiny
November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.
-
Opinion
A Uniform Federal Rule Would Curb Gen AI Missteps In Court
To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.
-
Riding The Changing Winds For AI Innovations At The USPTO
As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.
-
Series
The Law Firm Merger Diaries: Integrating Practice Groups
Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.
-
Opinion
Supreme Court Term Limits Would Carry Hidden Risk
While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.
-
Next Steps For Orgs. Amid Updated OpenAI Usage Policies
OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.
-
Series
Knitting Makes Me A Better Lawyer
Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.
-
How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation
On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.
-
Series
The Biz Court Digest: Welcome To Miami
After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.
-
Identifying And Resolving Conflicts Among Class Members
As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.
-
Adapting To A Plaintiff-Side Mindset For Patent Monetization
A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.
-
AI Evidence Rule Tweaks Encourage Judicial Guardrails
Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.
-
Series
The Law Firm Merger Diaries: Getting The Message Across
Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.
-
Opinion
Horizontal Stare Decisis Should Not Be Casually Discarded
Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.